ABUS

ABUS R&D to Revenue

179.23%Fiscal year

Period ending:

ABUS FY R&D/Revenue%
ABUS FY R&D/Revenue116105508.41%-12439875.90%
1998-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

ABUS r&d to revenue history

R&D spending as percentage of revenue. The available annual fiscal periods series contains 28 observations from Dec 31, 1998 to Dec 31, 2025.

Arbutus Biopharma Corp R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
179.2303%
875.6603%
406.2621%
216.3254%
596.123%
713.5956%
958.2599%
981.3559%
585.9813%
4,086.6667%
207.0719%
258%
138.7613%
127.8167%
0%
103,665,632.5074%
0%
0%
52.941%
33.2661%
65.9333%
183.3787%
867.6804%
426.0269%
371.4174%
493.0147%
679.2655%
704.8183%

Compare r&d to revenue

All ABUS financial metrics · ABUS stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.